Lonza Group AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 49 Fair Values set on narratives written by author
LONN Community Narratives
Vacaville And Visp Facilities Will Secure Future Biologics Demand
Vacaville And Visp Facilities Will Secure Future Biologics Demand
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside
Snowflake Analysis
Lonza Group AG Key Details
- 15.48
- 37.14%
- 15.73%
- 51.1%
About LONN
- Founded
- 1897
- Employees
- 20141
- CEO
- Website
View website
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.